Effects of Immunoglobulins G From Systemic Sclerosis Patients in Normal Dermal Fibroblasts: A Multi-Omics Study

Autoantibodies (Aabs) are frequent in systemic sclerosis (SSc). Although recognized as potent biomarkers, their pathogenic role is debated. This study explored the effect of purified immunoglobulin G (IgG) from SSc patients on protein and mRNA expression of dermal fibroblasts (FBs) using an innovative multi-omics approach. Dermal FBs were cultured in the presence of sera or purified IgG from patients with diffuse cutaneous SSc (dcSSc), limited cutaneous SSc or healthy controls (HCs). The FB proteome and transcriptome were explored using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) and microarray assays, respectively. Proteomic analysis identified 3,310 proteins. SSc sera and purified IgG induced singular protein profile patterns. These FB proteome changes depended on the Aab serotype, with a singular effect observed with purified IgG from anti-topoisomerase-I autoantibody (ATA) positive patients compared to HC or other SSc serotypes. IgG from ATA positive SSc patients induced enrichment in proteins involved in focal adhesion, cadherin binding, cytosolic part, or lytic vacuole. Multi-omics analysis was performed in two ways: first by restricting the analysis of the transcriptomic data to differentially expressed proteins; and secondly, by performing a global statistical analysis integrating proteomics and transcriptomics. Transcriptomic analysis distinguished 764 differentially expressed genes and revealed that IgG from dcSSc can induce extracellular matrix (ECM) remodeling changes in gene expression profiles in FB. Global statistical analysis integrating proteomics and transcriptomics confirmed that IgG from SSc can induce ECM remodeling and activate FB profiles. This effect depended on the serotype of the patient, suggesting that SSc Aab might play a pathogenic role in some SSc subsets.

[1]  D. Andersson,et al.  Passive transfer of fibromyalgia symptoms from patients to mice. , 2021, The Journal of clinical investigation.

[2]  D. Launay,et al.  Time for precision medicine in systemic sclerosis-associated pulmonary arterial hypertension , 2021, European Respiratory Journal.

[3]  Tammara A. Wood,et al.  Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement , 2020, Annals of the Rheumatic Diseases.

[4]  A. Gabrielli,et al.  Putative functional pathogenic autoantibodies in systemic sclerosis. , 2020, European journal of rheumatology.

[5]  M. Whitfield,et al.  Molecular "omic" signatures in systemic sclerosis. , 2020, European journal of rheumatology.

[6]  J. Inamo.  Association of differentially expressed genes and autoantibody type in patients with systemic sclerosis. , 2020, Rheumatology.

[7]  T. Shaw,et al.  Dissecting Fibroblast Heterogeneity in Health and Fibrotic Disease , 2020, Current Rheumatology Reports.

[8]  J. D. de Vries-Bouwstra,et al.  Association of Anti–Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti–Topoisomerase I–Positive Systemic Sclerosis , 2020, Arthritis & rheumatology.

[9]  Toshiyuki Yamamoto,et al.  Autophagy is involved in the sclerotic phase of systemic sclerosis , 2020, Fukushima journal of medical science.

[10]  F. Ingegnoli,et al.  Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis , 2020, Arthritis Research & Therapy.

[11]  Howard Y. Chang,et al.  GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways , 2019, Nature Communications.

[12]  C. D'Hulst,et al.  Intra-Sample Heterogeneity of Potato Starch Reveals Fluctuation of Starch-Binding Proteins According to Granule Morphology , 2019, Plants.

[13]  M. Cutolo,et al.  Antibodies against specific extractable nuclear antigens (ENAs) as diagnostic and prognostic tools and inducers of a profibrotic phenotype in cultured human skin fibroblasts: are they functional? , 2019, Arthritis Research & Therapy.

[14]  Olga Tanaseichuk,et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.

[15]  Kim-Anh Lê Cao,et al.  DIABLO: an integrative approach for identifying key molecular drivers from multi-omics assays , 2019, Bioinform..

[16]  L. Rudnicka,et al.  Antinuclear Antibodies in Systemic Sclerosis: an Update , 2019, Clinical Reviews in Allergy & Immunology.

[17]  F. Ingegnoli,et al.  Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts , 2018, Arthritis Research & Therapy.

[18]  E. Tinazzi,et al.  Gene Profiling in Patients with Systemic Sclerosis Reveals the Presence of Oncogenic Gene Signatures , 2018, Front. Immunol..

[19]  M. Mann,et al.  Deep Proteome Profiling Reveals Common Prevalence of MZB1‐Positive Plasma B Cells in Human Lung and Skin Fibrosis , 2017, American journal of respiratory and critical care medicine.

[20]  C. Denton,et al.  SYSTEMIC SCLEROSIS , 2008 .

[21]  K. Burridge.  Focal adhesions: a personal perspective on a half century of progress , 2017, The FEBS journal.

[22]  W. Wagner,et al.  Tubulin beta 3 and 4 are involved in the generation of early fibrotic stages. , 2017, Cellular signalling.

[23]  Lihua Zhang,et al.  Systematic approach to understanding the pathogenesis of systemic sclerosis , 2017, Clinical genetics.

[24]  I. Yakoub-Agha,et al.  Role of B cells in the pathogenesis of systemic sclerosis. , 2017, La Revue de medecine interne.

[25]  R. Nuti,et al.  Proteomic Investigation of Dermal Fibroblasts Isolated from Affected and Unaffected Skin Samples from Patients with Limited Cutaneous Systemic Sclerosis: 2 Distinct Entities? , 2017, The Journal of Rheumatology.

[26]  Jaclyn N. Taroni,et al.  Identification of Optimal Mouse Models of Systemic Sclerosis by Interspecies Comparative Genomics , 2016, Arthritis & rheumatology.

[27]  Marco Y. Hein,et al.  The Perseus computational platform for comprehensive analysis of (prote)omics data , 2016, Nature Methods.

[28]  Jing Chai,et al.  VennPainter: A Tool for the Comparison and Identification of Candidate Genes Based on Venn Diagrams , 2016, PloS one.

[29]  Jaclyn N. Taroni,et al.  Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures , 2015, Arthritis Research & Therapy.

[30]  Jaclyn N. Taroni,et al.  Experimentally-Derived Fibroblast Gene Signatures Identify Molecular Pathways Associated with Distinct Subsets of Systemic Sclerosis Patients in Three Independent Cohorts , 2015, PloS one.

[31]  Anuh T. George,et al.  Identification of Cadherin 11 as a Mediator of Dermal Fibrosis and Possible Role in Systemic Sclerosis , 2014, Arthritis & rheumatology.

[32]  A. Kühl,et al.  Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis , 2014, Arthritis Research & Therapy.

[33]  Tammara A. Wood,et al.  Molecular Signatures in Skin Associated with Clinical Improvement During Mycophenolate Treatment in Systemic Sclerosis , 2013, The Journal of investigative dermatology.

[34]  M. Koenig,et al.  Heparin inhibits the interaction of DNA topoisomerase I/anti-topoisomerase I immune complexes with heparan sulfate on dermal fibroblasts. , 2012, Arthritis and rheumatism.

[35]  M. Koenig,et al.  The autoantigen DNA topoisomerase I interacts with chemokine receptor 7 and exerts cytokine-like effects on dermal fibroblasts. , 2012, Arthritis and rheumatism.

[36]  R. Steele,et al.  The Association Between Disease Activity and Duration in Systemic Sclerosis , 2010, The Journal of Rheumatology.

[37]  M. Humbert,et al.  Antifibroblast antibodies from systemic sclerosis patients bind to α-enolase and are associated with interstitial lung disease , 2009, Annals of the rheumatic diseases.

[38]  R. Rezzonico,et al.  Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4. , 2008, Arthritis and rheumatism.

[39]  M. Koenig,et al.  Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies. , 2008, Autoimmunity reviews.

[40]  Sarah A. Pendergrass,et al.  Molecular Subsets in the Gene Expression Signatures of Scleroderma Skin , 2008, PloS one.

[41]  J. Dayer,et al.  Anti-fibroblast antibodies detected by cell-based ELISA in systemic sclerosis enhance the collagenolytic activity and matrix metalloproteinase-1 production in dermal fibroblasts. , 2007, Rheumatology.

[42]  T. Medsger,et al.  Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. , 2007, Arthritis and rheumatism.

[43]  A. Gabrielli,et al.  Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. , 2006, The New England journal of medicine.

[44]  J. Senécal,et al.  DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. , 2006, Arthritis and rheumatism.

[45]  M. Tremblay,et al.  Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. , 2004, Arthritis and rheumatism.

[46]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[47]  M. Gershwin,et al.  In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay. , 2003, Arthritis and rheumatism.

[48]  T. Medsger,et al.  Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. , 2003, Arthritis and rheumatism.

[49]  M. Fujimoto,et al.  Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. , 2003, The Journal of investigative dermatology.

[50]  A. Gabrielli,et al.  Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. , 2002, Arthritis and rheumatism.

[51]  M. Greaves,et al.  Antibodies to membranes of endothelial cells and fibroblasts in scleroderma , 1996, Clinical and experimental immunology.

[52]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[53]  K. Johnson.  An Update. , 1984, Journal of food protection.